



# NCCTG

NORTH CENTRAL CANCER TREATMENT GROUP

---

**Date:** 07 November 2007

**To:** Primary Clinical Research Associates

**From:** Lynn M Flickinger MA  
Research Protocol Specialist

**Re:** N0735, Phase II Trial of Albumin-Bound Paclitaxel in Combination with Gemcitabine and Bevacizumab in Patients with Metastatic Breast Cancer

The above study is now active.

The protocol and forms packet are enclosed. You may submit this protocol to your IRB for approval.

Please note: Remote registration will not be available for the first six patients who are enrolled in this study. These patients must have adverse event (AE) data for Cycle 1 submitted  $\leq 14$  days after completion of Cycle 1 (Section 18.0; Active-Monitoring Phase, Initial Material). Remote registration (and accrual) will be closed until all AE data from Cycle 1 are received for the first six patients. Please call the NCCTG Randomization Office to determine whether you are entering one of the first six patients.

This study was approved by the National Cancer Institute on October 29, 2008.

If you have any questions, please feel free to contact me: via email at [flickinger.lynn@mayo.edu](mailto:flickinger.lynn@mayo.edu) or telephone at 507-538-7035

Attachments